As for survival analysis, the high expression of FDX1 and SLC31A1 protein was associated with poor survival in glioma patients (p < 0.05 for FDX1 and p < 0.001 for SLC31A1, Figure 6C). Here, FDX1 is linked to central nervous system cancer.